Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy
Background A small minority of patients present with locally advanced cutaneous Squamous Cell Carcinoma (cSCC). The aim of this study was to evaluate the effectiveness of Tumour necrosis factor α (TNF) and melphalan based isolated limb perfusion (TM-ILP) as a limb saving strategy for locally advance...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2018-08, Vol.119 (4), p.429-434 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 434 |
|---|---|
| container_issue | 4 |
| container_start_page | 429 |
| container_title | British journal of cancer |
| container_volume | 119 |
| creator | Huis in ’t Veld, Eva A. Grünhagen, Dirk J. Deroose, Jan P. Nijsten, Tamar E. C. Wouters, Michel W. J. M. Verhoef, Cornelis van Houdt, Winan J. Hayes, Andrew J. |
| description | Background
A small minority of patients present with locally advanced cutaneous Squamous Cell Carcinoma (cSCC). The aim of this study was to evaluate the effectiveness of Tumour necrosis factor α (TNF) and melphalan based isolated limb perfusion (TM-ILP) as a limb saving strategy for locally advanced extremity cSCC.
Methods
A retrospective search from prospectively maintained databases, at two tertiary referral centers, was performed to identify patients treated with TM-ILP for locally advanced cSSC of an extremity between 2000 and 2015.
Results
A total of 30 patients treated with TM-ILP for cSCC were identified, with a median age of 71 years (36–92) and 50% female. Response could not be evaluated in 3 patients. After a median follow up of 25 months, the overall response rate was 81% (
n
= 22), with 16 patients having a complete response (CR, 59%). A total of 7 patients developed local recurrence, with a median time to recurrence of 9 months (Interquartile Range 7–10). Progressive disease was observed in 5 patients (19%). Limb salvage rate was 80%. The overall 2-year survival was 67%.
Conclusions
TM-ILP should be considered as an option in patients with locally advanced cSCC in specialised centers, resulting in a high limb salvage rate. |
| doi_str_mv | 10.1038/s41416-018-0149-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6133945</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2063720593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-4125423851b568a65870236ea89c590853e361471d18579c4511763c8d5573a53</originalsourceid><addsrcrecordid>eNp1UU1rFTEUDaLYWv0BbiTgxs1obr6DIEjxo1Bwo-uQl5d5pswkr8nMq6-_3gxT6we4CMnlnnvuOTkIPQfyGgjTbyoHDrIjoNvhprt9gE5BMNqBpuohOiWEqI4YSk7Qk1qvWmmIVo_RCTVGghLyFN1c1Dy4KWzxEMcN3ofSzzXmhPtc8JxKqMFPbjMEHH5MJYxxOmI_Ty6FPFdcr2c3Lg8fhgF7V3xMeXRvsUs49H0bjYewMld3iGmH61Tatt3xKXrUu6GGZ3f3Gfr28cPX88_d5ZdPF-fvLzvPFZk6DlRwyrSAjZDaSaEVoUwGp40XzYxggUngCraghTKeCwAlmddbIRRzgp2hdyvvft6MYetDagIGuy9xdOVos4v2706K3-0uH6wExgxfCF7dEZR8PYc62THWxe76BZYSyRQlwrAGffkP9CrPJTV7lsIi23BYCGFF-ZJrLaG_FwPELrHaNVbbYrVLrPa2zbz408X9xK8cG4CugNpaaRfK79X_Z_0JebevKw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2102369415</pqid></control><display><type>article</type><title>Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy</title><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Huis in ’t Veld, Eva A. ; Grünhagen, Dirk J. ; Deroose, Jan P. ; Nijsten, Tamar E. C. ; Wouters, Michel W. J. M. ; Verhoef, Cornelis ; van Houdt, Winan J. ; Hayes, Andrew J.</creator><creatorcontrib>Huis in ’t Veld, Eva A. ; Grünhagen, Dirk J. ; Deroose, Jan P. ; Nijsten, Tamar E. C. ; Wouters, Michel W. J. M. ; Verhoef, Cornelis ; van Houdt, Winan J. ; Hayes, Andrew J.</creatorcontrib><description>Background
A small minority of patients present with locally advanced cutaneous Squamous Cell Carcinoma (cSCC). The aim of this study was to evaluate the effectiveness of Tumour necrosis factor α (TNF) and melphalan based isolated limb perfusion (TM-ILP) as a limb saving strategy for locally advanced extremity cSCC.
Methods
A retrospective search from prospectively maintained databases, at two tertiary referral centers, was performed to identify patients treated with TM-ILP for locally advanced cSSC of an extremity between 2000 and 2015.
Results
A total of 30 patients treated with TM-ILP for cSCC were identified, with a median age of 71 years (36–92) and 50% female. Response could not be evaluated in 3 patients. After a median follow up of 25 months, the overall response rate was 81% (
n
= 22), with 16 patients having a complete response (CR, 59%). A total of 7 patients developed local recurrence, with a median time to recurrence of 9 months (Interquartile Range 7–10). Progressive disease was observed in 5 patients (19%). Limb salvage rate was 80%. The overall 2-year survival was 67%.
Conclusions
TM-ILP should be considered as an option in patients with locally advanced cSCC in specialised centers, resulting in a high limb salvage rate.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-018-0149-z</identifier><identifier>PMID: 29961756</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1813/1352 ; 692/4028/546 ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Drug Resistance ; Epidemiology ; Melphalan ; Molecular Medicine ; Oncology ; Perfusion ; Salvage ; Skin cancer ; Squamous cell carcinoma ; Tumor necrosis factor ; Tumor necrosis factor-TNF ; Tumors</subject><ispartof>British journal of cancer, 2018-08, Vol.119 (4), p.429-434</ispartof><rights>Cancer Research UK 2018</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-4125423851b568a65870236ea89c590853e361471d18579c4511763c8d5573a53</citedby><cites>FETCH-LOGICAL-c470t-4125423851b568a65870236ea89c590853e361471d18579c4511763c8d5573a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133945/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133945/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51297,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29961756$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huis in ’t Veld, Eva A.</creatorcontrib><creatorcontrib>Grünhagen, Dirk J.</creatorcontrib><creatorcontrib>Deroose, Jan P.</creatorcontrib><creatorcontrib>Nijsten, Tamar E. C.</creatorcontrib><creatorcontrib>Wouters, Michel W. J. M.</creatorcontrib><creatorcontrib>Verhoef, Cornelis</creatorcontrib><creatorcontrib>van Houdt, Winan J.</creatorcontrib><creatorcontrib>Hayes, Andrew J.</creatorcontrib><title>Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background
A small minority of patients present with locally advanced cutaneous Squamous Cell Carcinoma (cSCC). The aim of this study was to evaluate the effectiveness of Tumour necrosis factor α (TNF) and melphalan based isolated limb perfusion (TM-ILP) as a limb saving strategy for locally advanced extremity cSCC.
Methods
A retrospective search from prospectively maintained databases, at two tertiary referral centers, was performed to identify patients treated with TM-ILP for locally advanced cSSC of an extremity between 2000 and 2015.
Results
A total of 30 patients treated with TM-ILP for cSCC were identified, with a median age of 71 years (36–92) and 50% female. Response could not be evaluated in 3 patients. After a median follow up of 25 months, the overall response rate was 81% (
n
= 22), with 16 patients having a complete response (CR, 59%). A total of 7 patients developed local recurrence, with a median time to recurrence of 9 months (Interquartile Range 7–10). Progressive disease was observed in 5 patients (19%). Limb salvage rate was 80%. The overall 2-year survival was 67%.
Conclusions
TM-ILP should be considered as an option in patients with locally advanced cSCC in specialised centers, resulting in a high limb salvage rate.</description><subject>631/67/1813/1352</subject><subject>692/4028/546</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Melphalan</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Perfusion</subject><subject>Salvage</subject><subject>Skin cancer</subject><subject>Squamous cell carcinoma</subject><subject>Tumor necrosis factor</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNp1UU1rFTEUDaLYWv0BbiTgxs1obr6DIEjxo1Bwo-uQl5d5pswkr8nMq6-_3gxT6we4CMnlnnvuOTkIPQfyGgjTbyoHDrIjoNvhprt9gE5BMNqBpuohOiWEqI4YSk7Qk1qvWmmIVo_RCTVGghLyFN1c1Dy4KWzxEMcN3ofSzzXmhPtc8JxKqMFPbjMEHH5MJYxxOmI_Ty6FPFdcr2c3Lg8fhgF7V3xMeXRvsUs49H0bjYewMld3iGmH61Tatt3xKXrUu6GGZ3f3Gfr28cPX88_d5ZdPF-fvLzvPFZk6DlRwyrSAjZDaSaEVoUwGp40XzYxggUngCraghTKeCwAlmddbIRRzgp2hdyvvft6MYetDagIGuy9xdOVos4v2706K3-0uH6wExgxfCF7dEZR8PYc62THWxe76BZYSyRQlwrAGffkP9CrPJTV7lsIi23BYCGFF-ZJrLaG_FwPELrHaNVbbYrVLrPa2zbz408X9xK8cG4CugNpaaRfK79X_Z_0JebevKw</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Huis in ’t Veld, Eva A.</creator><creator>Grünhagen, Dirk J.</creator><creator>Deroose, Jan P.</creator><creator>Nijsten, Tamar E. C.</creator><creator>Wouters, Michel W. J. M.</creator><creator>Verhoef, Cornelis</creator><creator>van Houdt, Winan J.</creator><creator>Hayes, Andrew J.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201808</creationdate><title>Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy</title><author>Huis in ’t Veld, Eva A. ; Grünhagen, Dirk J. ; Deroose, Jan P. ; Nijsten, Tamar E. C. ; Wouters, Michel W. J. M. ; Verhoef, Cornelis ; van Houdt, Winan J. ; Hayes, Andrew J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-4125423851b568a65870236ea89c590853e361471d18579c4511763c8d5573a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>631/67/1813/1352</topic><topic>692/4028/546</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Melphalan</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Perfusion</topic><topic>Salvage</topic><topic>Skin cancer</topic><topic>Squamous cell carcinoma</topic><topic>Tumor necrosis factor</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huis in ’t Veld, Eva A.</creatorcontrib><creatorcontrib>Grünhagen, Dirk J.</creatorcontrib><creatorcontrib>Deroose, Jan P.</creatorcontrib><creatorcontrib>Nijsten, Tamar E. C.</creatorcontrib><creatorcontrib>Wouters, Michel W. J. M.</creatorcontrib><creatorcontrib>Verhoef, Cornelis</creatorcontrib><creatorcontrib>van Houdt, Winan J.</creatorcontrib><creatorcontrib>Hayes, Andrew J.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huis in ’t Veld, Eva A.</au><au>Grünhagen, Dirk J.</au><au>Deroose, Jan P.</au><au>Nijsten, Tamar E. C.</au><au>Wouters, Michel W. J. M.</au><au>Verhoef, Cornelis</au><au>van Houdt, Winan J.</au><au>Hayes, Andrew J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2018-08</date><risdate>2018</risdate><volume>119</volume><issue>4</issue><spage>429</spage><epage>434</epage><pages>429-434</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>Background
A small minority of patients present with locally advanced cutaneous Squamous Cell Carcinoma (cSCC). The aim of this study was to evaluate the effectiveness of Tumour necrosis factor α (TNF) and melphalan based isolated limb perfusion (TM-ILP) as a limb saving strategy for locally advanced extremity cSCC.
Methods
A retrospective search from prospectively maintained databases, at two tertiary referral centers, was performed to identify patients treated with TM-ILP for locally advanced cSSC of an extremity between 2000 and 2015.
Results
A total of 30 patients treated with TM-ILP for cSCC were identified, with a median age of 71 years (36–92) and 50% female. Response could not be evaluated in 3 patients. After a median follow up of 25 months, the overall response rate was 81% (
n
= 22), with 16 patients having a complete response (CR, 59%). A total of 7 patients developed local recurrence, with a median time to recurrence of 9 months (Interquartile Range 7–10). Progressive disease was observed in 5 patients (19%). Limb salvage rate was 80%. The overall 2-year survival was 67%.
Conclusions
TM-ILP should be considered as an option in patients with locally advanced cSCC in specialised centers, resulting in a high limb salvage rate.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>29961756</pmid><doi>10.1038/s41416-018-0149-z</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2018-08, Vol.119 (4), p.429-434 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6133945 |
| source | Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | 631/67/1813/1352 692/4028/546 Biomedical and Life Sciences Biomedicine Cancer Research Drug Resistance Epidemiology Melphalan Molecular Medicine Oncology Perfusion Salvage Skin cancer Squamous cell carcinoma Tumor necrosis factor Tumor necrosis factor-TNF Tumors |
| title | Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T03%3A07%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Isolated%20limb%20perfusion%20for%20unresectable%20extremity%20cutaneous%20squamous%20cell%20carcinoma;%20an%20effective%20limb%20saving%20strategy&rft.jtitle=British%20journal%20of%20cancer&rft.au=Huis%20in%20%E2%80%99t%20Veld,%20Eva%20A.&rft.date=2018-08&rft.volume=119&rft.issue=4&rft.spage=429&rft.epage=434&rft.pages=429-434&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-018-0149-z&rft_dat=%3Cproquest_pubme%3E2063720593%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2102369415&rft_id=info:pmid/29961756&rfr_iscdi=true |